Compare Cassava Sciences Inc (FLNA) vs Zillow Group Inc Class C (Z) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Zillow Group (Z) trades at $33.63, up 5.56% today, amid a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with revenue growing to $2.58B in 2025 and a return to profitability with net income of $23M, though margins remain thin. However, the stock faces significant headwinds from multiple securities fraud class action lawsuits filed in July 2026, alleging misconduct related to an anticompetitive agreement.

The outlook is cautious; while analyst consensus targets $57.67 implying substantial upside, legal risks and a high P/E ratio of 135.38 pose challenges. Investors should weigh the strong revenue growth and bullish technicals against the overhang of litigation and elevated valuation before considering a position.